Chr. Hansen Signs Agreement with Probiomics

November 23, 2009

1 Min Read
Chr. Hansen Signs Agreement with Probiomics

Hørsholm, DENMARKChr. Hansen signed an exclusive agreement with biotech company Probiomics Ltd., securing the rights to market the patented probiotic strain Lactobacillus fermentum PCC®, which has documented benefits to immune health.

The Australian Institute of Sport (AIS) and Chr. Hansen finalized a larger immune study in a group of 99 sports athletes. The double blinded, placebo-controlled study documented PCC was effective in reducing the severity and illness load of chest infection and medication use associated with respiratory tract infections (colds and flus) in males. Furthermore, the researchers found consuming PCC moderated the negative effects of exercise stress on the immune system. The study is expected to be published in 2010.



Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like